A report reviews the case of a patient with stage IV melanoma who, while having several issues with treatment toxicity, was later free of disease following treatment with BRAF and MEK inhibitors. BRAF ...
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Targeted ...
BRAF and MEK inhibitors are effective in treating resectable melanoma with BRAF V600 mutations, achieving significant pathological responses. The combination therapy significantly improves ...
“This is the first report of spindle cell sarcoma BRAF V600E/S607T double-mutated, responding to a combination of B-Raf and MEK inhibitors.” “This is the first report of spindle cell sarcoma BRAF ...
Pfizer’s phase 2 PHAROS trial of Braftovi plus Mektovi shows sustained long-term survival in patients with advanced lung cancer: New York Wednesday, October 22, 2025, 11:00 Hrs ...
PHILADELPHIA--(BUSINESS WIRE)--FORE Biotherapeutics today reported updated safety and efficacy data from the Phase 1/2a clinical trial evaluating plixorafenib (FORE8394; PLX8394), a novel, ...
Please provide your email address to receive an email when new articles are posted on . The triplet combination of vemurafenib/cobimetinib/atezolizumab showed ...
PHILADELPHIA--(BUSINESS WIRE)--FORE Biotherapeutics today announced new nonclinical data related to plixorafenib (FORE8394; formerly PLX8394), the company's novel, investigational, small-molecule, ...
In patients with BRAF-mutated non–small-cell lung cancer (NSCLC), further research is needed to identify more treatment options that address the scope of subsets in this population. Non-V600 mutations ...
Interstitial Lung Disease (ILD): In the PHAROS trial, 1 patient (1%) receiving MEKTOVI with BRAFTOVI developed pneumonitis. Assess new or progressive unexplained pulmonary symptoms or findings for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback